_ COMPANY OVERVIEW

Oculus BioMed is developing the next-generation standard of ocular therapies, which are designed to better preserve and improve vision in patients with retinal and cornea disorders including diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).

While many biotech companies pursue a single scientific platform, we are strategically building a deep and diverse pipeline of genetic therapies, novel small peptide drugs and advanced medical devices.

Oculus BioMed is developing the next-generation standard of ocular therapies, which are designed to better preserve and improve vision in patients with retinal and cornea disorders including diabetic macular edema (DME), neovascular age-related macular degeneration (nAMD).

We are a pre-clinical and clinical stage ocular company developing a pipeline of advanced therapeutics based on our proprietary OBM-1701 synthetic peptide for wAMD, OBM-17XX for dry eye disease (DED) and cornea replacement technology.

Moreover, OBM has partnered with world leading research institute – The Centre for Eye Research Australia (“CERA”) to develop “SwitchGene” eye gene therapies including but not limited to its potential use in treating diabetic retinopathy (DR).

oculus-biomed
problem-solving
_ NEWS

Latest News from Oculus Biomed

November 27, 2023
Published by admin on November 27, 2023
Categories
Mr Roger McPherson appointed CFO / Company Secretary
27 Nov 2023
OBM is delighted to welcome Roger to the executive team. He brings significant technical skill and industry experience to the company. Roger has more than 30 […]
Do you like it?12
0 Read more
November 1, 2023
Published by admin on November 1, 2023
Categories
AusBiotech conference Brisbane
1 – 3 Nov 2023
OBM recently attended Australias premier biotechnology conference in Brisbane – represented by CEO Andrew Coloretti & Non-Executive Director Michelle Gallaher. The conference included valuable one-on-one private […]
Do you like it?10
0 Read more
October 9, 2023
Published by admin on October 9, 2023
Categories
Oculus BioMed Limited partners with The Centre for Eye Research Australia (CERA) in a deal to develop “SwitchGene” – Eye Gene therapies.
11 Oct 2023
Oculus BioMed (OBM) an ophthalmology focused biotechnology company, entered into a collaboration agreement with CERA – Centre for Eye Research Australia regarding the development of a therapeutic […]
Do you like it?8
0 Read more
October 1, 2023
Published by admin on October 1, 2023
Categories
Ms Michelle Gallaher appointed Non-Executive Director
01 Oct 2023
OBM is delighted to welcome Michelle to the Board. She is an exceptional person and professional and brings significant industry experience and skill to the company. […]
Do you like it?7
0 Read more
August 28, 2023
Published by admin on August 28, 2023
Categories
Tan Tock Seng Hospital (Singapore) site visit by CEO
2nd August 2023
OBM’s CEO was invited by Dr. Rupesh Agrawal – Deputy Research Head at Singapore’s Tan Tock Seng Hospital (TTSH) to tour the Ophthalmology department research facilities […]
Do you like it?6
0 Read more
August 28, 2023
Published by admin on August 28, 2023
Categories
ACRO Biomedicals & Krisan Biotech site visit – Tainan, Taiwan
25th July 2023
OBM’s CEO & CSO held meetings with the company’s key business and scientific partners –ACRO Biomedical’s & Krisan Biotech CEO’s (D.J. Hsieh & Jamie Hung respectively) […]
Do you like it?4
0 Read more
ALL NEWS FROM OCULUS
_ OUR TEAM

Oculus BioMed’s Team

LEADERSHIP TEAM
SCIENTIFIC BOARD / ADVISORY
Bio-med